William Douglas Figg

This paper detects and monitors translocation renal cell carcinoma (tRCC) using plasma cell-free epigenomic profiling, achieving high accuracy in distinguishing tRCC from other cancers and healthy controls.

This study uses proteogenomics to identify ancestry-specific and shared molecular drivers in prostate cancer, revealing distinct biological programs and improving risk prediction.

This study compares genomic alterations and transcriptional phenotypes in circulating tumor DNA and matched metastatic tumors in SCLC patients, finding cfDNA reflects tumor mutations, identifies resistance mechanisms, and tracks tumor evolution.